Treatment Information

Back

Liver Cancer treatment details. Chemotherapy, Immunotherapy.

California Pacific Medical Center, San Francisco, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:San Francisco, CA
Treatments:Chemotherapy, ImmunotherapyHospital:California Pacific Medical Center
Drugs:Journal:Link
Date:Sep 2009

Description:

Patients:
This phase 2 study involved hepatocellular carcinoma patients who were divided into two separate treatment groups. Group A had 14 patients with an average age of 59.2 years and 71.4% were male. Group B had 14 patients with an average age of 60.4 years and 85.7% were male.

Treatment:
Patients in group A were treated with transarterial chemoembolization with doxorubicin or cisplatin (chemotherapy) and with the immunotherapy agent called thymalfasin, which helps growth and regulation of T-cells and supports the anti-tumor effects of the immune system.

Patients in group B were treated with transarterial chemoembolization with doxorubicin or cisplatin (chemotherapy) only.

Toxicities:
There were three adverse event-related deaths in group A, but the specific causes were not given. Nausea and fatigue were also reported.

There was one adverse event-related death in group B, but the specific cause was not given. Nausea, fatigue and bacterial infections were also reported.

Results:
The median overall survival times for groups A and B were 25.4 and 13.1 months, respectively.

Support:
This study was supported by SciClone Pharmaceuticals.

Correspondence: Dr. Robert G. Gish; email: [email protected]



Back